Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 20/20 | 0.66 |
| ▸ | PTGER2 | P43116 | 7/20 | 0.66 |
| ▸ | PTGDR | Q13258 | 6/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27645382 | 1.00 | PTGER4 (0.66) | PTGER4PTGER2PTGDR | |
| SCHEMBL5360697 | 0.92 | PTGER4 (0.76) | PTGER4PTGER2PTGDR | |
| SCHEMBL5367029 | 0.90 | PTGER4 (0.57) | PTGER4PTGER2PTGDR | |
| SCHEMBL691395 | 0.85 | PTGER4 (0.73) | PTGER4PTGER2PTGDR | |
| SCHEMBL19714256 | 0.85 | PTGER4 (0.73) | PTGER4PTGER2PTGDR | |
| SCHEMBL4454319 | 0.85 | PTGER4 (0.67) | PTGER4PTGER2PTGDR | |
| SCHEMBL4014640 | 0.84 | PTGER4 (0.72) | PTGER4PTGER2PTGDR | |
| SCHEMBL5361496 | 0.82 | PTGER4 (0.66) | PTGER4PTGER2PTGDR | |
| SCHEMBL692250 | 0.80 | PTGER4 (0.61) | PTGER4PTGER2PTGDR | |
| SCHEMBL5187980 | 0.80 | PTGER4 (0.61) | PTGER4PTGER2PTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663979-B1 | PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS | RAQUALIA PHARMA INC (JP) | 2013-10-09 | — | — | EP | disclosed |
| EP-1663979-B1 | PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS | RAQUALIA PHARMA INC (JP) | 2013-10-09 | — | — | EP | disclosed |
| CN-1867551-B | Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists | RAQUALIA PHARMA INC | 2013-09-11 | — | — | CN | disclosed |
| US-7238714-B2 | Aryl or heteroaryl amide compounds | PFIZER JAPAN, INC. (JP) | 2007-07-03 | — | — | US | disclosed |
| US-7238714-B2 | Aryl or heteroaryl amide compounds | PFIZER JAPAN, INC. (JP) | 2007-07-03 | — | — | US | disclosed |
| US-7238714-B2 | Aryl or heteroaryl amide compounds | PFIZER JAPAN, INC. (JP) | 2007-07-03 | — | — | US | disclosed |
| CN-1867551-A | Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists | PFIZER (US) | 2006-11-22 | — | — | CN | disclosed |
| US-20050065188-A1 | Aryl or heteroaryl amide compounds | ASKAT INC. (JP) | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065188-A1 | Aryl or heteroaryl amide compounds | HRH2, PTGER1, LTB4R2 | PTGER4 13/4885PTGER2 11/4885PTGDR 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.